Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07635316 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Feb 25, 2027 → Jun 30, 2027
See other at-risk trials from Novartis

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Feb 25, 2027 to Jun 30, 2027
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 3 of 10 entries
  2. Recruitment opened
    • Study sites: 0 to 1
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 34 trials at risk
This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.
Trial Details
NCT Number NCT07635316
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Gastroenteropancreatic Neuroendocrine Tumor
Related terms Gastro-enteropancreatic neuroendocrine tumor
Enrollment 4,023 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov